Compare OLPX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLPX | CDNA |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | 2007 |
| Metric | OLPX | CDNA |
|---|---|---|
| Price | $2.04 | $21.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $1.89 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 2.6M | 652.5K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $422,960,000.00 | $48,324,000.00 |
| Revenue This Year | $2.95 | $16.01 |
| Revenue Next Year | $3.39 | $11.31 |
| P/E Ratio | ★ N/A | $429.80 |
| Revenue Growth | 0.07 | ★ 18.93 |
| 52 Week Low | $0.99 | $10.96 |
| 52 Week High | $2.04 | $23.24 |
| Indicator | OLPX | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 63.86 | 59.06 |
| Support Level | $2.02 | $15.80 |
| Resistance Level | N/A | $22.89 |
| Average True Range (ATR) | 0.01 | 1.00 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 75.00 | 76.54 |
Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, and DTC channels. The company derives its revenue through the sale of its hair care products. The company generates the majority of revenue from Professional sales channels followed by Specialty Retail and then DTC. Geographically the company generates the majority of its revenue from the International market.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.